{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:08:04Z","timestamp":1790352484088,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015626","name":"Melanoma Institute Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015626","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2021\/GNT2007839"],"award-info":[{"award-number":["2021\/GNT2007839"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2022\/GNT2018514"],"award-info":[{"award-number":["2022\/GNT2018514"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ejca.2023.113506","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T11:25:46Z","timestamp":1703589946000},"page":"113506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy"],"prefix":"10.1016","volume":"198","author":[{"given":"Aljosja","family":"Rogiers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4529-3372","authenticated-orcid":false,"given":"Florentia","family":"Dimitriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1170-9915","authenticated-orcid":false,"given":"Irene","family":"Lobon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael A.","family":"Vergara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Pires da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serigne N.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2023.113506_bib1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2023.113506_bib2","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2023.113506_bib3","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.113506_bib4","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.113506_bib5","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.18.01998","article-title":"Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb\/IV CheckMate 511 Trial","volume":"37","author":"Lebbe","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.113506_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001072","article-title":"Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"8","author":"Lee","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2023.113506_bib7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2023.113506_bib8","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-021-01406-6","article-title":"Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade","volume":"27","author":"Andrews","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2023.113506_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","article-title":"Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors","volume":"107","author":"Hasan Ali","year":"2019","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2023.113506_bib10","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1158\/2326-6066.CIR-18-0487","article-title":"The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy","volume":"6","author":"Young","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"10.1016\/j.ejca.2023.113506_bib11","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","article-title":"Understanding and treating the inflammatory adverse events of cancer immunotherapy","volume":"184","author":"Dougan","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ejca.2023.113506_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell"},{"issue":"21","key":"10.1016\/j.ejca.2023.113506_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.157839","article-title":"Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis","volume":"7","author":"Nahar","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.ejca.2023.113506_bib14","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/s41467-021-21572-y","article-title":"Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis","volume":"12","author":"Hutchinson","year":"2021","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.ejca.2023.113506_bib15","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41590-022-01274-3","article-title":"PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine","volume":"23","author":"Herati","year":"2022","journal-title":"Nat Immunol"},{"issue":"9","key":"10.1016\/j.ejca.2023.113506_bib16","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S1470-2045(17)30428-X","article-title":"Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial","volume":"18","author":"Long","year":"2017","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2023.113506_bib17","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.113506_bib18","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes","volume":"104","author":"Tsang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ejca.2023.113506_bib19","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jaad.2003.09.021","article-title":"Seasonal variations in the diagnosis of cutaneous melanoma","volume":"50","author":"Schmid-Wendtner","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.113506_bib20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2021.04.045","article-title":"Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy","volume":"153","author":"Dearden","year":"2021","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2023.113506_bib21","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma","volume":"32","author":"Owen","year":"2021","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2023.113506_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"36","key":"10.1016\/j.ejca.2023.113506_bib23","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113506_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40364-020-00209-0","article-title":"Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors","volume":"8","author":"Bai","year":"2020","journal-title":"Biomark Res"},{"issue":"2","key":"10.1016\/j.ejca.2023.113506_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003625","article-title":"Germline biomarkers predict toxicity to anti-PD1\/PDL1 checkpoint therapy","volume":"10","author":"Weidhaas","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2023.113506_bib26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/14737159.2018.1440209","article-title":"Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead","volume":"18","author":"Patil","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"issue":"1","key":"10.1016\/j.ejca.2023.113506_bib27","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13046-020-01749-x","article-title":"The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors","volume":"39","author":"Jia","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.113506_bib28","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejca.2021.08.031","article-title":"Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy","volume":"157","author":"Dimitriou","year":"2021","journal-title":"Eur J Cancer"},{"issue":"16","key":"10.1016\/j.ejca.2023.113506_bib29","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2023.113506_bib30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1183\/09031936.00194610","article-title":"Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study","volume":"39","author":"Jenkins","year":"2012","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ejca.2023.113506_bib31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12931-020-01421-0","article-title":"Trends and seasonal variation of hospitalization and mortality of interstitial lung disease in the United States from 2006 to 2016","volume":"21","author":"Ho","year":"2020","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.ejca.2023.113506_bib32","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00165-2019","article-title":"Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study","volume":"6","author":"Pozzessere","year":"2020","journal-title":"ERJ Open Res"},{"issue":"1","key":"10.1016\/j.ejca.2023.113506_bib33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4103\/2249-4863.152263","article-title":"Seasonality of hepatitis: a review update","volume":"4","author":"Fares","year":"2015","journal-title":"J Fam Med Prim Care"},{"issue":"6","key":"10.1016\/j.ejca.2023.113506_bib34","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/hep.24597","article-title":"Seasonal variation in the patient diagnosis of primary biliary cirrhosis: further evidence for an environmental component to etiology","volume":"54","author":"McNally","year":"2011","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.ejca.2023.113506_bib35","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1136\/thoraxjnl-2016-209032","article-title":"Seasonal variation in incidence of sarcoidosis: a population-based study, 1976-2013","volume":"71","author":"Ungprasert","year":"2016","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.ejca.2023.113506_bib36","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/ki.1996.495","article-title":"Goodpasture's syndrome","volume":"50","author":"Bolton","year":"1996","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.ejca.2023.113506_bib37","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/aje\/152.6.558","article-title":"Incidence of stroke and season of the year: evidence of an association","volume":"152","author":"Oberg","year":"2000","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.ejca.2023.113506_bib38","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00001648-200203000-00017","article-title":"Seasonal variation in hospital discharge diagnosis of atrial fibrillation: a population-based study","volume":"13","author":"Frost","year":"2002","journal-title":"Epidemiology"},{"issue":"3","key":"10.1016\/j.ejca.2023.113506_bib39","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ijcard.2003.10.026","article-title":"Secular trends and seasonality in first-time hospitalization for acute myocardial infarction--a Danish population-based study","volume":"97","author":"Fischer","year":"2004","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.ejca.2023.113506_bib40","doi-asserted-by":"crossref","first-page":"16729","DOI":"10.1038\/s41598-022-19898-8","article-title":"Investigating the effects of absolute humidity and movement on COVID-19 seasonality in the United States","volume":"12","author":"Lin","year":"2022","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.ejca.2023.113506_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001296","article-title":"Global patterns in seasonal activity of influenza A\/H3N2, A\/H1N1, and B from 1997 to 2005: viral coexistence and latitudinal gradients","volume":"2","author":"Finkelman","year":"2007","journal-title":"PLoS One"},{"issue":"44","key":"10.1016\/j.ejca.2023.113506_bib42","doi-asserted-by":"crossref","first-page":"27456","DOI":"10.1073\/pnas.2008590117","article-title":"Seasonality and uncertainty in global COVID-19 growth rates","volume":"117","author":"Merow","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.ejca.2023.113506_bib43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/oxfordjournals.aje.a121575","article-title":"Recurrent outbreaks of measles, chickenpox and mumps. I. Seasonal variation in contact rates","volume":"98","author":"London","year":"1973","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1016\/j.ejca.2023.113506_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002172","article-title":"Unraveling the Transmission Ecology of Polio","volume":"13","author":"Martinez-Bakker","year":"2015","journal-title":"PLoS Biol"},{"issue":"4","key":"10.1016\/j.ejca.2023.113506_bib45","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1461-0248.2005.00879.x","article-title":"Seasonality and the dynamics of infectious diseases","volume":"9","author":"Altizer","year":"2006","journal-title":"Ecol Lett"},{"issue":"21","key":"10.1016\/j.ejca.2023.113506_bib46","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ejca.2023.113506_bib47","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/pcmr.13072","article-title":"Seasonal variation in effect of anti-PD-1 initiation on overall survival among patients with advanced melanoma","volume":"36","author":"Ellebaek","year":"2023","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ejca.2023.113506_bib48","article-title":"Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort","author":"Borgers","year":"2023","journal-title":"Pigment Cell Melanoma Res"},{"issue":"12","key":"10.1016\/j.ejca.2023.113506_bib49","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.bcp.2010.07.041","article-title":"Melatonin: a pleiotropic molecule regulating inflammation","volume":"80","author":"Radogna","year":"2010","journal-title":"Biochem Pharm"},{"issue":"4","key":"10.1016\/j.ejca.2023.113506_bib50","doi-asserted-by":"crossref","first-page":"8638","DOI":"10.3390\/ijms14048638","article-title":"Melatonin: buffering the immune system","volume":"14","author":"Carrillo-Vico","year":"2013","journal-title":"Int J Mol Sci"},{"issue":"24","key":"10.1016\/j.ejca.2023.113506_bib51","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1016\/j.vaccine.2016.04.032","article-title":"Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomised trial","volume":"34","author":"Long","year":"2016","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.ejca.2023.113506_bib52","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S1470-2045(21)00546-5","article-title":"Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study","volume":"22","author":"Qian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7917","key":"10.1016\/j.ejca.2023.113506_bib53","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41586-022-04875-y","article-title":"The metastatic spread of breast cancer accelerates during sleep","volume":"607","author":"Diamantopoulou","year":"2022","journal-title":"Nature"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923008080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923008080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T16:35:46Z","timestamp":1721666146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923008080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":53,"alternative-id":["S0959804923008080"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113506","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113506"}}